ZNTL Zentalis Pharmaceuticals, Inc.: institutional ownership and insider trading
124 funds reported holding $239M of Zentalis Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net bought $20.6M, with 33 new positions and 19 funds selling out; over the last 12 months insiders bought $22.9M and sold $10.1M on the open market.
Famous investors holding ZNTL
- Two Sigma (Two Sigma Investments): $14.7M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $7.80M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $11.3M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $3.22M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $2.65M, 0.0% of the portfolio
Largest institutional holders of ZNTL
- Squadron Capital Management LLC — $20.0M
- 5AM Venture Management, LLC — $19.1M
- BlackRock, Inc. (BLK) — $18.2M
- TWO SIGMA INVESTMENTS, LP — $14.7M
- VANGUARD CAPITAL MANAGEMENT LLC — $13.8M
- ACADIAN ASSET MANAGEMENT LLC — $13.0M
- CITADEL ADVISORS LLC — $11.3M
- RENAISSANCE TECHNOLOGIES LLC — $7.80M
- Opaleye Management Inc. — $6.85M
- ORBIMED ADVISORS LLC — $6.74M
Recent ZNTL insider trades
- Aug 14, 2026: Walters Group bought 4,335,000 shares ($15.2M)
- Feb 10, 2026: Vultaggio Vincent sold 40,224 shares ($97.5K)
- Feb 9, 2026: Eastland Julia Marie sold 8,755 shares ($21.2K)
- Feb 9, 2026: Bruns Ingmar sold 3,297 shares ($8.00K)
5%+ owners
- Walters William T: 18.8% (Schedule 13G/A, filed Aug 19, 2026)
- BlackRock, Inc.: 5.2% (Schedule 13G, filed Jul 30, 2026)